Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab biosimilar in Black and non-Black patients with metastatic triple negative and ER-positive, HER2-negative breast cancer.

Trial Details

NCT ID

NCT05846789

Phase

PHASE2

Sponsor

Kathy Miller

Status

RECRUITING

Cancer Type

Triple Negative (TNBC) Breast Cancer

Interventions

SOC Chemotherapy
Tocilizumab

Locations (sample)

Atlanta, Georgia, United States|33.749,-84.38798
Carmel, Indiana, United States|39.97837,-86.11804
Indianapolis, Indiana, United States|39.76838,-86.15804
Indianapolis, Indiana, United States|39.76838,-86.15804
Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

≥ 18 years old at the time of informed consent
Ability to provide written informed consent and HIPAA authorization
Locally recurrent (not amenable to local therapy with curative intent) or metastatic breast cancer that is triple negative or ER-positive (ER and P…
For patients with TNBC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →